Agneta Walhagen

Corporate Officer/Principal bei

LEO Pharma AB

66 Jahre

Consumer Services

Health Technology

Profil

Agneta Walhagen currently works at LEO Pharma AB, as Senior Director.
Dr. Walhagen also formerly worked at Iconovo AB, as Independent Director from 2019 to 2025.
Dr. Walhagen received his graduate degree and doctorate degree from the University of Lund.

Aktive Positionen von Agneta Walhagen

Unternehmen	Position	Beginn
LEO Pharma AB LEO Pharma AB LEO Pharma AB is an independent, Swedish research-driven pharmaceutical company specializing in dermatology, with a history spanning over 100 years from its origins in Copenhagen. The company is based in Malmö, Sweden. The company employs approximately 5,200 people worldwide and serves 92 million patients across 130 countries. LEO Pharma is majority-owned by the independent LEO Foundation, with Nordic Capital holding a minority stake. Its Nordic hub operates in Sweden, with about 25 employees focused on sales, marketing, medical affairs, and supply. The company’s product portfolio includes dermatological and thrombotic treatments.	Corporate Officer/Principal	-

Alle aktiven Positionen von Agneta Walhagen

Ehemalige bekannte Positionen von Agneta Walhagen

Unternehmen	Position	Ende
ICONOVO AB	Direktor/Vorstandsmitglied	09.06.2025

Sehen Sie sich die Erfahrung von Agneta Walhagen im Detail an

Ausbildung von Agneta Walhagen

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Agneta Walhagen im Detail an

Unternehmensverbindungen

Private Unternehmen	3
University of Lund University of Lund Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
LEO Pharma AB LEO Pharma AB LEO Pharma AB is an independent, Swedish research-driven pharmaceutical company specializing in dermatology, with a history spanning over 100 years from its origins in Copenhagen. The company is based in Malmö, Sweden. The company employs approximately 5,200 people worldwide and serves 92 million patients across 130 countries. LEO Pharma is majority-owned by the independent LEO Foundation, with Nordic Capital holding a minority stake. Its Nordic hub operates in Sweden, with about 25 employees focused on sales, marketing, medical affairs, and supply. The company’s product portfolio includes dermatological and thrombotic treatments.
Iconovo AB Iconovo AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that manufactures and wholesales powder-based inhalation drugs and devices	Health Technology